Alzignomics' Liver Cancer Drug 'RZ-001' Receives FDA Regenerative Medicine Advanced Therapy Designation

"Expecting Benefits from the Expedited Development Program"

Alzignomics' liver cancer treatment candidate 'RZ-001' has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA). Following its designation as an orphan drug in 2024 and fast track status in 2025, RZ-001 has now additionally secured the benefits of the FDA's expedited development program through the RMAT designation.

Algonomics company logo image. Algonomics

On May 7 (local time), Alzignomics announced that the RMAT designation process was completed as an FDA review project manager (PM) was assigned to the case.

The RMAT program is granted to regenerative medicine candidates that have demonstrated innovation and therapeutic potential in early clinical trials for serious or life-threatening diseases. Once designated, companies can closely consult with the FDA regarding clinical and approval strategies. Regulatory benefits such as priority review, rolling review, and accelerated approval are applied. The program was introduced in 2016 under the 21st Century Cures Act. Because preliminary clinical evidence is required to demonstrate the potential to address unmet medical needs, the threshold for designation is high.

RZ-001 is a treatment for primary hepatocellular carcinoma (HCC) developed using Alzignomics' proprietary ribozyme-based RNA editing platform. The company confirmed meaningful early signals in interim results of its Phase 1b/2a clinical trial presented at the American Association for Cancer Research (AACR 2026) in April, and believes the FDA recognized the clinical potential based on these results.

Alzignomics Vice President Hong Sungwoo stated, "With this designation, we will accelerate discussions with the FDA on clinical design, CMC, and commercialization strategies and speed up partnership development." CEO Lee Sungwook added, "This is a result of the FDA acknowledging the innovativeness of our RNA editing platform. We will focus our capabilities on global development and commercialization."

This content was produced with the assistance of AI translation services.